Welcome to our dedicated page for Molina Hlthcare SEC filings (Ticker: MOH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Molina Healthcare, Inc. filings document the regulatory record for a managed healthcare company serving Medicaid, Medicare and state insurance marketplace programs. Its 8-K reports disclose operating results, premium revenue and earnings guidance, Regulation FD investor presentations, material agreements, direct financial obligations, impairment charges and senior unsecured note financing.
The company's proxy and governance filings cover annual meeting proposals, director and executive compensation matters, equity incentive plan authorization and amendments to charter or bylaw provisions such as stockholder special-meeting rights. The filing record also describes capital-structure terms, credit agreement covenants, risk-factor references and shareholder voting outcomes.
Molina Healthcare, Inc. reports 2025 results showing strong top-line growth but sharply lower earnings in a challenging government-paid healthcare environment. Total revenue rose to $45,426 million from $40,650 million, driven by Medicaid, Medicare, Marketplace and the ConnectiCare acquisition.
Premium revenue reached $43,052 million, yet the medical care ratio worsened to 91.7% from 89.1%, compressing profitability. Net income fell to $472 million from $1,179 million, and diluted EPS decreased to $8.92 from $20.42. Membership ended 2025 at 5.49 million, with Medicaid at 4.57 million and Marketplace up to 655,000.
The company outlines a strategy focused on government-sponsored programs, targeting 11%–13% long-term growth and more than $50 billion in premium revenue by 2027. It highlights about $9 billion of new annual premium from 2025 RFP wins and acquisitions, while also planning a major repositioning: exiting its MAPD product for 2027 and cutting Marketplace exposure after an expected roughly 50% revenue decline in 2026.
Molina Healthcare, Inc. amended its credit agreement on February 4, 2026, temporarily easing a key debt covenant. The required minimum quarterly interest coverage ratio was reduced from 3.00:1.00 to 1.75:1.00 for quarters ending March 31 through December 31, 2026, then stepped up to 2.00:1.00 for March 31, 2027, 2.50:1.00 for June 30, 2027, and 2.75:1.00 for September 30, 2027.
The company also determined on February 5, 2026 that it will record an estimated non-cash, pre-tax impairment charge of approximately $93 million in the first quarter of 2026, tied to certain intangible assets. This follows a decision to exit its Medicare Advantage Prescription Drug product for 2027 to focus exclusively on dual eligible Medicare members. The charge will be recorded outside of adjusted net income.
Molina Healthcare, Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and year ended December 31, 2025, as well as full-year 2026 revenue and earnings guidance.
The press release is provided as Exhibit 99.1 to the report, and any information on the company’s website referenced in that release is expressly excluded from being part of this report.
FMR LLC filed a Schedule 13G reporting beneficial ownership of 2,969,387.80 shares of Molina Healthcare common stock, representing 5.8% of the class as of 12/31/2025. FMR LLC reports sole voting power over 2,802,222.73 shares and sole dispositive power over 2,969,387.80 shares.
Abigail P. Johnson is also a reporting person, with sole dispositive power over 2,969,387.80 shares and no voting power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control, other than activities solely in connection with a nomination under Rule 240.14a-11.
One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of Molina Healthcare’s common stock.
BlackRock, Inc. has filed an amended Schedule 13G reporting beneficial ownership of Molina Healthcare common stock as of December 31, 2025. BlackRock reports beneficial ownership of 3,524,452 shares of Molina Healthcare, representing 6.9% of the outstanding common stock.
BlackRock has sole voting power over 3,296,986 shares and sole dispositive power over 3,524,452 shares, with no shared voting or dispositive power. The stake is held through various BlackRock business units and underlying clients, and no single other person has an interest in more than five percent of Molina’s outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Molina Healthcare.
Molina Healthcare director reports quarterly stock grant under equity plan
A director of Molina Healthcare, Inc. received a grant of 317 shares of common stock on January 1, 2026 under the company’s 2025 Equity Incentive Plan, in connection with service as a director. The grant value was based on an annual equity award of $220,000 per director, with one quarter, or $55,000, granted on the first day of each quarter.
Because January 1, 2026 was a non-trading day, the share amount was calculated using the $173.54 closing price of Molina Healthcare common stock on December 31, 2025. Following this transaction, the reporting person beneficially owned 17,325 shares held by a family trust and 1,500 shares held in the reporting person’s 401(k) plan, all reported as indirect ownership.
Molina Healthcare, Inc. reported an insider equity award to one of its directors. On January 1, 2026, the director received 317 shares of common stock as a grant under the company’s 2025 Equity Incentive Plan for board service. The award represents one quarter of an annual equity value of $220,000, with this quarterly portion set at $55,000.
The number of shares was calculated using the common stock closing price of $173.54 on December 31, 2025. Following this grant, the director directly beneficially owns 3,742 shares of Molina Healthcare common stock.
Molina Healthcare director Ronna Romney, through the Ronna Romney Revocable Trust, received a grant of 317 shares of common stock on January 1, 2026 under the company’s 2025 Equity Incentive Plan for her services as a director. The quarterly grant amount was based on an equity value of $55,000, using the $173.54 closing price of Molina Healthcare’s common stock on December 31, 2025 because January 1 was a non-trading day.
Following this grant, the trust beneficially owns 17,733 shares of Molina Healthcare common stock. The filing indicates this Form 4 is for a single reporting person and reflects routine, formula-based director compensation rather than an open-market purchase or sale.
Molina Healthcare, Inc. reported that one of its directors received a grant of common stock as part of the company’s equity compensation program. On January 1, 2026, the director was granted 317 shares of Molina Healthcare common stock under the company’s 2025 Equity Incentive Plan for services as a director. The quarterly equity award was set at a dollar value of $55,000, determined by dividing that amount by the stock’s closing price of $173.54 on December 31, 2025, resulting in the 317-share grant. Following this transaction, the director beneficially owned 11,669 shares of Molina Healthcare common stock, held directly.
Molina Healthcare, Inc. reported that Director Richard C. Zoretic received a quarterly stock grant under the company’s 2025 Equity Incentive Plan for his board service. The award is part of an annual equity grant valued at $220,000 for each director, paid in four quarterly installments of $55,000.
For the quarter beginning January 1, 2026, the grant was set at 317 shares of common stock, calculated using the December 31, 2025 closing price of $173.54 because January 1 was a non-trading day. After this transaction, 7,947 shares of Molina Healthcare common stock are reported as beneficially owned indirectly through the Richard Charles Zoretic Revocable Living Trust.